0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Moleculin Biotech Inc

Healthcare US MBRX

4.3082USD
-0.0418(0.96%)

Last update at 2024-04-25T20:00:00Z

Day Range

4.284.50
LowHigh

52 Week Range

0.341.35
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -29.02500M -15.89400M -17.35500M -13.43400M -11.87600M
Minority interest - - - - -
Net income -27.41000M -8.86000M -14.99600M -13.20500M -11.87600M
Selling general administrative 11.67M 8.39M 6.79M 6.31M 5.30M
Selling and marketing expenses - - - - -
Gross profit - -0.16400M - - 0.00000M
Reconciled depreciation 0.13M 0.16M 0.20M 0.20M 0.07M
Ebit -30.64000M -22.96800M -19.74200M -17.52400M -18.27800M
Ebitda -31.97500M -29.53200M -21.88800M -21.38700M -18.21000M
Depreciation and amortization -1.33500M -6.56400M -2.14600M -3.86300M 0.07M
Non operating income net other - - 2.37M 4.08M 3.15M
Operating income -30.64000M -22.96800M -19.74200M -17.52400M -15.02500M
Other operating expenses 30.64M 22.97M 19.74M 17.52M 15.03M
Interest expense -1.61500M 7.07M 0.01M 8.15M 0.00000M
Tax provision - - 0.00000M -0.22900M -
Interest income 0.24M 0.31M - 4.08M 3.19M
Net interest income 0.24M 0.31M 0.01M 0.01M 0.00400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.61500M -7.03400M -2.35900M -0.22900M 3.15M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 30.64M 22.97M 19.74M 17.52M 15.03M
Cost of revenue - 0.16M - - 0.00000M
Total other income expense net 1.61M 7.07M 2.39M 4.09M 3.15M
Discontinued operations - - - - -
Net income from continuing ops -29.02500M -15.89400M -17.35500M -13.20500M -11.87600M
Net income applicable to common shares - -15.89400M -17.35500M -13.20500M -11.87600M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 57.42M 84.09M 29.03M 25.23M 19.59M
Intangible assets 11.15M 11.15M 11.15M 11.15M 11.15M
Earning assets - - - - -
Other current assets 2.45M 1.59M 0.16M 0.53M 0.84M
Total liab 5.23M 5.10M 11.27M 9.66M 5.31M
Total stockholder equity 52.19M 78.99M 17.76M 15.57M 14.27M
Deferred long term liab - - - 5.82M 1.44M
Other current liab -0.11600M 2.16M 1.67M 0.16M 2.63M
Common stock 0.03M 0.03M 0.07M 0.05M 0.03M
Capital stock 0.03M 0.03M 0.07M 0.05M 0.03M
Retained earnings -101.83500M -72.81000M -56.91600M -39.56100M -26.35600M
Other liab - 1.41M 8.19M 5.82M 1.44M
Good will - - - - -
Other assets - - 0.69M - -
Cash 43.15M 70.90M 15.17M 10.73M 7.13M
Cash and equivalents - - - - -
Total current liabilities 4.82M 3.62M 2.92M 3.57M 3.88M
Current deferred revenue - - - 1.15M -
Net debt -42.69400M -70.74400M -14.89600M -10.35600M -7.13400M
Short term debt 0.12M 0.10M 0.12M 0.10M 0.18M
Short long term debt - - - - -
Short long term debt total 0.45M 0.16M 0.28M 0.38M -
Other stockholder equity 153.99M 151.73M 74.54M 55.05M 40.56M
Property plant equipment - 0.45M 0.69M 0.60M 0.46M
Total current assets 45.60M 72.50M 17.20M 13.48M 7.97M
Long term investments - - - - -
Net tangible assets - 67.84M 6.61M 4.42M 3.12M
Short term investments - - - - -
Net receivables 0.02M 0.04M 0.00100M 0.01M 0.06M
Long term debt - - - - -
Inventory -0.02200M -0.04500M 1.86M 2.21M -
Accounts payable 4.82M 1.36M 1.13M 2.15M 1.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.01M 0.04M 0.07M 0.03M 0.04M
Additional paid in capital - - - - -
Common stock total equity - - 0.07M 0.05M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - -56.91600M -39.56100M -26.35600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.28M 0.34M - 11.15M 11.15M
Deferred long term asset charges - - - - -
Non current assets total 11.83M 11.59M 11.83M 11.75M 11.61M
Capital lease obligations 0.45M 0.16M 0.28M 0.38M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.06700M -0.01900M -0.37400M -0.05100M -0.41700M
Change to liabilities - 0.23M -1.02400M -0.23300M 1.86M
Total cashflows from investing activities - -0.01900M -0.37400M -0.05100M -0.41700M
Net borrowings - - - - -
Total cash from financing activities -0.02300M 74.72M 22.55M 20.85M 12.04M
Change to operating activities - 0.80M 0.98M -3.04900M 1.17M
Net income -29.02500M -15.89400M -17.35500M -13.20500M -11.87600M
Change in cash -27.75800M 55.73M 4.44M 3.60M -0.58000M
Begin period cash flow 70.90M 15.17M 10.73M 7.13M 7.71M
End period cash flow 43.15M 70.90M 15.17M 10.73M 7.13M
Total cash from operating activities -27.63900M -18.95100M -17.77100M -17.19800M -12.20300M
Issuance of capital stock 0.00000M 74.68M 22.56M 19.29M 12.03M
Depreciation 0.13M 0.16M 0.20M 0.20M 0.07M
Other cashflows from investing activities - - 0.00200M 0.00100M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - 0.13M - -
Sale purchase of stock - - 22.57M 20.85M 12.04M
Other cashflows from financing activities -0.02300M 0.04M -0.01200M 1.56M 0.02M
Change to netincome - -4.25900M -0.57500M -2.52600M -2.00500M
Capital expenditures 0.07M 0.02M 0.38M 0.05M 0.42M
Change receivables - - - - -
Cash flows other operating - - 0.81M -1.43300M -0.25200M
Exchange rate changes - - - - -0.00500M
Cash and cash equivalents changes - - 4.40M 3.60M -0.58000M
Change in working capital 0.22M 1.04M -0.04100M -2.14200M 1.61M
Stock based compensation 2.27M 2.37M 1.68M 1.54M 1.14M
Other non cash items -1.24300M 0.10M 0.09M 0.48M -3.14500M
Free cash flow -27.70600M -18.97000M -18.14700M -17.25000M -12.62000M

Fundamentals

  • Previous Close 4.35
  • Market Cap20.27M
  • Volume22594
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-27.63600M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.89

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
MBRX
Moleculin Biotech Inc		 -0.0418 0.96% 4.31 - - - 0.57 0.15
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech Inc

5300 Memorial Drive, Houston, TX, United States, 77007

Key Executives

Name Title Year Born
Mr. Walter V. Klemp Founder, Chairman, Pres & CEO 1960
Mr. Jonathan P. Foster CPA Exec. VP & CFO 1964
Dr. Donald H. Picker Ph.D. Chief Scientific Officer 1946
Dr. Waldemar Priebe Ph.D. Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board NA
Dr. Robert C. Shepard FACP, M.D., F.A.C.P. Chief Medical Officer of Annamycin 1952
Dr. John Paul Waymack M.D., Sc.D. Sr. Chief Medical Officer 1952
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer of New Products 1955
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. European Chief Medical Officer NA
Ms. Jacqueline Northcut Consultant 1962
Mr. Louis Ploth Jr. Independent Advisor 1954

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).